Matthew Mossanen1, Filipe L F Carvalho1, Vinayak Muralidhar2, Mark A Preston1, Brendan Reardon3, Jake R Conway3, Catherine Curran3, Dory Freeman3, Sybil Sha4, Guru Sonpavde3, Michelle Hirsch5, Adam S Kibel1, Eliezer M Van Allen6, Kent W Mouw7. 1. Division of Urologic Surgery, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA. 2. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA; Kaiser Permanente Northwest, Portland, OR, USA. 3. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 4. Geisel School of Medicine at Dartmouth, Hanover, NH, USA. 5. Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. 6. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu. 7. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: kent_mouw@dfci.harvard.edu.
Abstract
BACKGROUND: Muscle-invasive bladder cancer (MIBC) is a rare but serious event following definitive radiation for prostate cancer. Radiation-associated MIBC (RA-MIBC) can be difficult to manage given the challenges of delivering definitive therapy to a previously irradiated pelvis. The genomic landscape of RA-MIBC and whether it is distinct from non-RA-MIBC are unknown. OBJECTIVE: To define mutational features of RA-MIBC and compare the genomic landscape of RA-MIBC with that of non-RA-MIBC. DESIGN, SETTING, AND PARTICIPANTS: We identified patients from our institution who received radiotherapy for prostate cancer and subsequently developed MIBC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed whole exome sequencing of bladder tumors from RA-MIBC patients. Tumor genetic alterations including mutations, copy number alterations, and mutational signatures were identified and were compared with genetic features of non-RA-MIBC. We used the Kaplan-Meier method to estimate recurrence-free (RFS) and overall (OS) survival. RESULTS AND LIMITATIONS: We identified 19 RA-MIBC patients with available tumor tissue (n = 22 tumors) and clinical data. The median age was 76 yr, and the median time from prostate cancer radiation to RA-MIBC was 12 yr. The median RFS was 14.5 mo and the median OS was 22.0 mo. Compared with a cohort of non-RA-MIBC analyzed in parallel, there was no difference in tumor mutational burden, but RA-MIBCs had a significantly increased number of short insertions and deletions (indels) consistent with previous radiation exposure. We identified mutation signatures characteristic of APOBEC-mediated mutagenesis, aging, and homologous recombination deficiency. The frequency of mutations in many known bladder cancer genes, including TP53, KDM6A, and RB1, as well as copy number alterations such as CDKN2A loss was similar in RA-MIBC and non-RA-MIBC. CONCLUSIONS: We identified unique mutational properties that likely contribute to the distinct biological and clinical features of RA-MIBC. PATIENT SUMMARY: Bladder cancer is a rare but serious diagnosis following radiation for prostate cancer. We characterized genetic features of bladder tumors arising after prostate radiotherapy, and identify similarities with and differences from bladder tumors from patients without previous radiation.
BACKGROUND: Muscle-invasive bladder cancer (MIBC) is a rare but serious event following definitive radiation for prostate cancer. Radiation-associated MIBC (RA-MIBC) can be difficult to manage given the challenges of delivering definitive therapy to a previously irradiated pelvis. The genomic landscape of RA-MIBC and whether it is distinct from non-RA-MIBC are unknown. OBJECTIVE: To define mutational features of RA-MIBC and compare the genomic landscape of RA-MIBC with that of non-RA-MIBC. DESIGN, SETTING, AND PARTICIPANTS: We identified patients from our institution who received radiotherapy for prostate cancer and subsequently developed MIBC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We performed whole exome sequencing of bladder tumors from RA-MIBC patients. Tumor genetic alterations including mutations, copy number alterations, and mutational signatures were identified and were compared with genetic features of non-RA-MIBC. We used the Kaplan-Meier method to estimate recurrence-free (RFS) and overall (OS) survival. RESULTS AND LIMITATIONS: We identified 19 RA-MIBC patients with available tumor tissue (n = 22 tumors) and clinical data. The median age was 76 yr, and the median time from prostate cancer radiation to RA-MIBC was 12 yr. The median RFS was 14.5 mo and the median OS was 22.0 mo. Compared with a cohort of non-RA-MIBC analyzed in parallel, there was no difference in tumor mutational burden, but RA-MIBCs had a significantly increased number of short insertions and deletions (indels) consistent with previous radiation exposure. We identified mutation signatures characteristic of APOBEC-mediated mutagenesis, aging, and homologous recombination deficiency. The frequency of mutations in many known bladder cancer genes, including TP53, KDM6A, and RB1, as well as copy number alterations such as CDKN2A loss was similar in RA-MIBC and non-RA-MIBC. CONCLUSIONS: We identified unique mutational properties that likely contribute to the distinct biological and clinical features of RA-MIBC. PATIENT SUMMARY: Bladder cancer is a rare but serious diagnosis following radiation for prostate cancer. We characterized genetic features of bladder tumors arising after prostate radiotherapy, and identify similarities with and differences from bladder tumors from patients without previous radiation.
Authors: Kristian Cibulskis; Aaron McKenna; Tim Fennell; Eric Banks; Mark DePristo; Gad Getz Journal: Bioinformatics Date: 2011-07-29 Impact factor: 6.937
Authors: Jakob Hedegaard; Philippe Lamy; Iver Nordentoft; Ferran Algaba; Søren Høyer; Benedicte Parm Ulhøi; Søren Vang; Thomas Reinert; Gregers G Hermann; Karin Mogensen; Mathilde Borg Houlberg Thomsen; Morten Muhlig Nielsen; Mirari Marquez; Ulrika Segersten; Mattias Aine; Mattias Höglund; Karin Birkenkamp-Demtröder; Niels Fristrup; Michael Borre; Arndt Hartmann; Robert Stöhr; Sven Wach; Bastian Keck; Anna Katharina Seitz; Roman Nawroth; Tobias Maurer; Cane Tulic; Tatjana Simic; Kerstin Junker; Marcus Horstmann; Niels Harving; Astrid Christine Petersen; M Luz Calle; Ewout W Steyerberg; Willemien Beukers; Kim E M van Kessel; Jørgen Bjerggaard Jensen; Jakob Skou Pedersen; Per-Uno Malmström; Núria Malats; Francisco X Real; Ellen C Zwarthoff; Torben Falck Ørntoft; Lars Dyrskjøt Journal: Cancer Cell Date: 2016-06-16 Impact factor: 31.743
Authors: Stanley L Liauw; John E Sylvester; Christopher G Morris; John C Blasko; Peter D Grimm Journal: Int J Radiat Oncol Biol Phys Date: 2006-08-02 Impact factor: 7.038
Authors: Sophia C Kamran; Amy Berrington de Gonzalez; Andrea Ng; Daphne Haas-Kogan; Akila N Viswanathan Journal: Cancer Date: 2016-03-07 Impact factor: 6.860
Authors: Sybil T Sha; Edward Christopher Dee; Matthew Mossanen; Brandon A Mahal; Cierra Zaslowe-Dude; Trevor J Royce; Michelle S Hirsch; Guru Sonpavde; Mark A Preston; Paul L Nguyen; Kent W Mouw; Vinayak Muralidhar Journal: Urology Date: 2021-04-20 Impact factor: 2.649
Authors: Kristian Cibulskis; Michael S Lawrence; Scott L Carter; Andrey Sivachenko; David Jaffe; Carrie Sougnez; Stacey Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz Journal: Nat Biotechnol Date: 2013-02-10 Impact factor: 54.908
Authors: Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway Journal: Nat Med Date: 2014-05-18 Impact factor: 53.440